Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Nov;28(11):1376-85.
doi: 10.1093/ajh/hpv031. Epub 2015 Mar 23.

The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension: A Meta-Analysis of Randomized and Nonrandomized Studies

Khagendra Dahal  1 , Sumit Kunwar  2 , Jharendra Rijal  3 , Fahad Alqatahni  4 , Raju Panta  2 , Noshi Ishak  5 , Roy Patterson Russell  5
Affiliations
Meta-Analysis

The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension: A Meta-Analysis of Randomized and Nonrandomized Studies

Khagendra Dahal et al. Am J Hypertens. 2015 Nov.

Abstract

Background: A few studies have shown aldosterone antagonists (AA) to be effective therapy in patients with resistant hypertension (RH). We performed a meta-analysis of randomized and nonrandomized studies of AA in patients with RH.

Methods: We searched PUBMED, EMBASE, and CENTRAL for studies on the use of AA in patients with RH. Meta-analysis was performed using random-effects model. The change in office and ambulatory blood pressures (BP), effects on biochemical profile, change in the number of antihypertensive agents, and adverse events were main outcomes.

Results: We included 15 studies (3 randomized controlled trials, 1 nonrandomized comparative study, and 11 single-arm studies) with 1,204 total patients in the meta-analysis. In comparative studies, AA reduced systolic BP (SBP) by 24.26 mm Hg (95% CI: 8.65-39.87, P = 0.002) and diastolic BP (DBP) by 7.79 mm Hg (3.79-11.79, P = 0.0001). Similarly, AA reduced SBP by 22.74 mm Hg (18.21-27.27, P < 0.00001) and DBP by 10.49 mm Hg (8.85-12.13, P < 0.00001) in single-arm studies. AA resulted in significant change in serum electrolytes in single-arm studies but not in comparative studies. Significantly more adverse events were noted in single-arm studies but not in comparative studies.

Conclusions: On the basis of the current meta-analysis, we conclude that AA is safe and effective therapy in patients with RH.

Keywords: aldosterone antagonists; blood pressure; eplerenone; hypertension; meta-analysis; resistant hypertension; spironolactone..

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Emerging Pharmacological Approaches for the Treatment of Arterial Hypertension.
    Schinzari F, Montenero R, Cardillo C, Tesauro M. Schinzari F, et al. Biomedicines. 2025 Mar 25;13(4):790. doi: 10.3390/biomedicines13040790. Biomedicines. 2025. PMID: 40299361 Free PMC article. Review.
  • Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
    Krishnan SM, Ling YH, Huuskes BM, Ferens DM, Saini N, Chan CT, Diep H, Kett MM, Samuel CS, Kemp-Harper BK, Robertson AAB, Cooper MA, Peter K, Latz E, Mansell AS, Sobey CG, Drummond GR, Vinh A. Krishnan SM, et al. Cardiovasc Res. 2019 Mar 15;115(4):776-787. doi: 10.1093/cvr/cvy252. Cardiovasc Res. 2019. PMID: 30357309 Free PMC article.
  • Brazilian Guidelines of Hypertension - 2020.
    Barroso WKS, Rodrigues CIS, Bortolotto LA, Mota-Gomes MA, Brandão AA, Feitosa ADM, Machado CA, Poli-de-Figueiredo CE, Amodeo C, Mion Júnior D, Barbosa ECD, Nobre F, Guimarães ICB, Vilela-Martin JF, Yugar-Toledo JC, Magalhães MEC, Neves MFT, Jardim PCBV, Miranda RD, Póvoa RMDS, Fuchs SC, Alessi A, Lucena AJG, Avezum A, Sousa ALL, Pio-Abreu A, Sposito AC, Pierin AMG, Paiva AMG, Spinelli ACS, Nogueira ADR, Dinamarco N, Eibel B, Forjaz CLM, Zanini CRO, Souza CB, Souza DDSM, Nilson EAF, Costa EFA, Freitas EV, Duarte EDR, Muxfeldt ES, Lima Júnior E, Campana EMG, Cesarino EJ, Marques F, Argenta F, Consolim-Colombo FM, Baptista FS, Almeida FA, Borelli FAO, Fuchs FD, Plavnik FL, Salles GF, Feitosa GS, Silva GVD, Guerra GM, Moreno Júnior H, Finimundi HC, Back IC, Oliveira Filho JB, Gemelli JR, Mill JG, Ribeiro JM, Lotaif LAD, Costa LSD, Magalhães LBNC, Drager LF, Martin LC, Scala LCN, Almeida MQ, Gowdak MMG, Klein MRST, Malachias MVB, Kuschnir MCC, Pinheiro ME, Borba MHE, Moreira Filho O, Passarelli Júnior O, Coelho OR, Vitorino PVO, Ribeiro Junior RM, Esporcatte R, Franco R, Pedrosa R, Mulinari RA, Paula RB, Okawa RTP, Rosa RF, Amaral SLD, Ferreira-Filho SR, Kaiser SE, Jardim TSV, Guimarãe… See abstract for full author list ➔ Barroso WKS, et al. Arq Bras Cardiol. 2021 Mar;116(3):516-658. doi: 10.36660/abc.20201238. Arq Bras Cardiol. 2021. PMID: 33909761 Free PMC article. English, Portuguese. No abstract available.
  • Consensus paper on the evaluation and treatment of resistant hypertension by the Turkish Society of Cardiology.
    Sahinarslan A, Gazi E, Aktoz M, Ozkan C, Ulusal Okyay G, Ucar Elalmis O, Belen E, Bitigen RA, Derici U, Bascil Tutuncu N, Yildirir A. Sahinarslan A, et al. Anatol J Cardiol. 2020 Sep;24(3):137-152. doi: 10.14744/AnatolJCardiol.2020.74154. Anatol J Cardiol. 2020. PMID: 32870176 Free PMC article. No abstract available.
  • Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
    Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK, Caulfield MJ, Padmanabhan S, Mackenzie IS, Salsbury J, Brown MJ; British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group. Williams B, et al. Lancet Diabetes Endocrinol. 2018 Jun;6(6):464-475. doi: 10.1016/S2213-8587(18)30071-8. Epub 2018 Apr 11. Lancet Diabetes Endocrinol. 2018. PMID: 29655877 Free PMC article.
See all "Cited by" articles

Publication types

MeSH terms

Substances